• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    27x P B For Alpha Tau Medical (DRTS) Following FDA REGAIN Trial Expansion?

    Simply Wall St·10/21/2026 05:39:06
    语音播报

    Alpha Tau Medical (NasdaqCM:DRTS) drew fresh attention after the FDA approved a supplement expanding its REGAIN trial in recurrent glioblastoma, and regulators cleared the first interim data presentation at a major neuro-oncology conference.

    At a share price of $13.09, Alpha Tau Medical has given investors a 171.01% year-to-date share price return. The 1-year total shareholder return of 211.67% and 3-year total shareholder return of 274.00% point to strong longer-term gains, even as the 30-day share price return declined 14.11%. This suggests short-term momentum has cooled after a sharp run-up into this latest FDA and conference news.

    Harness this momentum in Alpha Tau Medical and scan for other high-potential healthcare trials with the 37 healthcare AI stocks.

    So is Alpha Tau Medical’s surge a clean read on progress in the glioblastoma program, or is it mostly a sentiment swing around a thinly traded clinical story, as the current price tag implies?

    Preferred Price-to-Book of 27.4x: Is it justified?

    Valuation has sprinted far ahead of the financials. At $13.09 per share, Alpha Tau Medical trades on a P/B ratio of 27.4x, even though it currently reports no revenue and a net loss of $92.57m.

    P/B compares the market value of the equity to the accounting value of net assets. For a clinical-stage oncology group like Alpha Tau Medical, that metric often reflects investor expectations around future trial outcomes and eventual commercialization rather than current earnings power.

    The gap to peers is significant. The US Medical Equipment industry trades on an average P/B of 2.4x, while close peers average 5.8x. The 27.4x multiple is therefore many turns richer than both the sector and peer benchmarks. This signals that a lot of optimism around pipeline progress and future revenue growth is already embedded in the share price.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-book of 27.4x (OVERVALUED).

    Still, the Alpha Tau Medical story can change quickly if REGAIN data underwhelm, or if fresh equity raises dilute holders at today’s elevated price-to-book ratio.

    Find out about the key risks to this Alpha Tau Medical narrative.

    Next Steps

    Sentiment around Alpha Tau Medical is clearly split, which is exactly why this is the moment to look through the numbers, weigh the clinical setup, and decide whether the trade-off between potential upside and real downside risk fits your own approach, starting with the 1 key reward and 2 important warning signs.

    Looking for more Alpha Tau Medical sized opportunities?

    If Alpha Tau Medical has your attention, do not stop here. Broader idea hunting with structured tools can quickly sharpen your watchlist and highlight fresh angles.